First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
Oral semaglutide reduced both first and recurrent heart attacks and strokes in high-risk people with type 2 diabetes, lowering overall cardiovascular burden.
This secondary analysis of a randomized clinical trial examined First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial. Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo, highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and mortality in this high-risk population.
What the study was
- Study design
- Secondary analysis of a randomized clinical trial
- Sample size
- 9650
- Category
- Prevention
- Maturity
- Validated
- Journal
- JAMA cardiology
Why it surfaced
Retained after review of PubMed metadata and abstract because its secondary analysis of a randomized clinical trial directly informs cardiovascular-metabolic; scoring was capped conservatively for design and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.